K. KumarSankhalaMD

PubMed

• Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma.
  Kesari, S., Wagle, N., Carrillo, J., Sharma, A., Nguyen, M., Truong, J., Gill, J., Nersesian, R., Nomura, N., Rahbarlayegh, E., Barkhoudarian, G., Sivakumar, W., Kelly...> ;Clinical Cancer Research. 2024 Jan 17
• 23 citations
  Combined Central Retinal Artery and Vein Occlusion with Ischemic Optic Neuropathy After COVID-19 Vaccination.
  Sol Lee, Kamalesh K Sankhala, Swaraj Bose, Ron P Gallemore> ;International Medical Case Reports Journal. 2022 Jan 1
• 12 citations
  A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
  Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R. Diamond, Sant P. Chawla, Anthony W. Tolcher, Patricia LoRusso, Joseph Paul Eder, Martin Gutierrez, Kumar Sankh...> ;Clinical Cancer Research. 2021 Sep 13
• 29 citations
  Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors.
  Antje Wick, Oliver Bähr, Martin Schuler, Kristoffer Staal Rohrberg, Sant P. Chawla, Filip Janku, David Schiff, Volker Heinemann, Yoshitaka Narita, Heinz-Josef Lenz, Ma...> ;Clinical Cancer Research. 2021 Feb 23
• 16 citations
  A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, ...
  Neeta Somaiah, Sant P. Chawla, Matthew S. Block, John C. Morris, Khanh T. Do, Joseph Kim, Mihaela Druta, Kamalesh Kumar Sankhala, Patrick Hwu, Robin L. Jones, Sacha Gn...> ;Oncoimmunology. 2020 Nov 19
• 1 citations
  Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules.
  Kamalesh Kumar Sankhala, Chris H. Takimoto, Alain C. Mita, Henry Xiong, Jordi Rodon, Amir Mehrvarz Sarshekeh, K. Burns, Kenzo Iizuka, Scott Kopetz> ;Investigational New Drugs. 2019 Feb 1
• 36 citations
  Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced ...
  Monica M. Mita, Alain C. Mita, Jennifer L. Moseley, Jennifer Poon, Karen Small, Ying Ming Jou, Paul Kirschmeier, Da Zhang, Yali Zhu, Paul Statkevich, K. K. Sankhala, J...> ;British Journal of Cancer. 2017 Aug 31
• 1 citations
  Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies
  Kamalesh Kumar Sankhala> ;Expert Opinion on Investigational Drugs. 2017 Mar 20
• 77 citations
  First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial
  Sant P. Chawla, Zsuzsanna Papai, Guzel Mukhametshina, Kamalesh Kumar Sankhala, Leonid Vasylyev, Alexander Fedenko, Kenneth Khamly, Kristen N. Ganjoo, Rajnish Nagarkar,...> ;JAMA Oncology. 2015 Dec 1
• 20 citations
  A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.
  Sant P. Chawla, Victoria S. Chua, Andrew F. Hendifar, Doris Quon, Neelesh Soman, Kamalesh Kumar Sankhala, D. Scott Wieland, Daniel J. Levitt> ;Cancer. 2015 Feb 15
• 29 citations
  Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors
  Devalingam Mahalingam, John Nemunaitis, Laeeq Malik, John Sarantopoulos, Steven D. Weitman, Kamalesh Kumar Sankhala, Jessica Hart, Ahmed Kousba, Nicole S. Gallegos, Ga...> ;Cancer Chemotherapy and Pharmacology. 2014 Oct 11
• 15 citations
  A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors
  Monica M. Mita, Michael S. Gordon, Narmyn Rejeb, Athos Gianella-Borradori, V. Jego, Alain C. Mita, John Sarantopoulos, K. K. Sankhala, D. Mendelson> ;Targeted Oncology. 2014 Sep 1
• 26 citations
  Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib...
  Devalingam Mahalingam, Laeeq Malik, Muralidhar Beeram, J. Rodon, Kamalesh Kumar Sankhala, Alain C. Mita, Daniel Benjamin, Norma S. Ketchum, Joel E. Michalek, Anthony W...> ;Cancer Chemotherapy and Pharmacology. 2014 May 10
• 105 citations
  Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer
  Monica M. Mita, Anil A. Joy, Alain C. Mita, Kamalesh Kumar Sankhala, Ying Ming Jou, Da Zhang, Paul Statkevich, Yali Zhu, Siu Long Yao, Karen Small, Rajat Bannerji, Cha...> ;Clinical Breast Cancer. 2014 Jun 1
• 5 citations
  Partial response of a rare malignant metastatic diffuse tenosynovial giant cell tumor with benign histologic features, treated with SCH 717–454, an insulin growth fact...
  Swati Sikaria, Josefine Heim-Hall, Elizabeth H. Diaz, Ronald P. Williams, K. K. Sankhala, Brenda Laabs, Monica M. Mita> ;Targeted Oncology. 2014 Jan 1
• 35 citations
  Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia
  Hagop M. Kantarjian, S. Padmanabhan, Wendy Stock, Martin S. Tallman, Gregory A. Curt, J. Li, Anna Osmukhina, K. Wu, Dennis Huszar, G. Borthukar, Stephan Faderl, G. Gar...> ;Investigational New Drugs. 2012 Jun 1
• 192 citations
  Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
  Sant P. Chawla, Arthur P. Staddon, Laurence H. Baker, Scott M. Schuetze, Anthony W. Tolcher, Gina Z. D'Amato, Jean-Yves Blay, Monica M. Mita, Kamalesh Kumar Sankhala, ...> ;Journal of Clinical Oncology. 2012 Jan 1
• 28 citations
  Heat shock proteins: a potential anticancer target.
  Kamalesh Kumar Sankhala, Monica M. Mita, Alain C. Mita, Chris H. Takimoto> ;Current Drug Targets. 2011 Nov 30
• Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm phase Ib trial in combination with five standard ...
  Sankhala KK, Tolcher AW, Mita MM, Gordon MS, Rosen LS, Papadopoulos KP, Patnaik A, Drengler RL, Mita AC, Sarantopoulos J, Bristow RG, Fine G, Choy GS, Azab M> ;J. Clin. Oncol.. 2011-05-20
• A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results.
  Mita MM, Mita AC, Moseley J, Poon J, Small KA, Jou Y, Kirschmeier P, Zhang D, Statkevich P, Sankhala KK, Sarantopoulos J, Cleary JM, Chirieac LR, Rodig S, Bannerji R, ...> ;J. Clin. Oncol.. 2011-05-20
• Phase I study of ATI-1123, a novel human serum albumin-stabilized docetaxel liposomal formulation, in patients with advanced solid malignancies.
  Vemulapalli S, Mita AC, Gallegos NS, Anderson G, Charles J, Rogers JM, Kousba A, Sankhala KK, Nemunaitis JJ> ;J. Clin. Oncol.. 2011-05-20
• 13 citations
  Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
  Kamalesh Kumar Sankhala, Devesh M. Pandya, John Sarantopoulos, Scott A. Soefje, Francis J. Giles, Sant P. Chawla> ;Expert Opinion on Drug Metabolism & Toxicology. 2009 Nov 24
• 3 citations
  Potential of mTOR inhibitors as therapeutic agents in hematological malignancies
  Kamalesh Kumar Sankhala, Francis J. Giles> ;Expert Review of Hematology. 2009 Aug 1
• 5 citations
  Review: desmoplastic small round cell tumor: current treatment approach and role of targeted therapy.
  Kamalesh Kumar Sankhala, Sant P. Chawla> ;Clinical Advances in Hematology & Oncology. 2009 Jul 1
• A phase II study of intravenous (IV) wild-type reovirus (Reolysin) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung.
  Mita AC, Sankhala K, Sarantopoulos J, Carmona J, Okuno S, Goel S, Chugh R, Coffey MC, Mettinger K, Mita MM> ;J. Clin. Oncol.. 2009-05-20
• Join now to see all